sotalol has been researched along with Chronic Disease in 34 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the effects of pretreatment with oral d,l-sotalol on rate-dependent changes in atrial monophasic action potential (MAP) duration after cardioversion of chronic AF with reference to the efficacy in preventing the arrhythmia recurrence." | 9.11 | Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence. ( Ito, A; Kodama, I; Osaka, T; Yamazaki, M; Yokoyama, E, 2004) |
| "To compare the efficacy and safety of sotalol and quinidine after conversion of atrial fibrillation (AF) of <6 months, a prospective multicenter trial enrolled 121 patients who were randomized to receive dl-sotalol (160 to 320 mg/day, 58 patients) or quinidine sulfate (600 to 800 mg/day, 63 patients)." | 9.09 | Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo. ( de Paola, AA; Veloso, HH, 1999) |
| "To compare the effects of sotalol and metoprolol on heart rate, during isotonic (ITE) and isometric (IME) exercise and daily activities, in digitalized patients with chronic atrial fibrillation." | 9.09 | Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. ( Igoumenidis, NE; Kalebubas, MD; Kanoupakis, EM; Kochiadakis, GE; Mavrakis, HE; Vardakis, KE; Vardas, PE, 2001) |
| "Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven." | 9.08 | Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. ( Ferrick, KJ; Fisher, JD; Gallik, DM; Kim, SG; Roth, JA, 1997) |
| "To establish the value of adjuvant dl-sotalol to digoxin for control of the ventricular response in chronic atrial fibrillation, 60 patients were evaluated in a multicenter, randomized, double-blind, parallel, placebo-controlled study." | 9.07 | Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. ( Bellinger, R; Brodsky, M; Powers, L; Saini, R; Weiss, R; Zoble, R, 1994) |
| " Its relative efficacy towards suppressing chronic ventricular arrhythmia was tested by comparison with propranolol." | 9.06 | Randomized double blind trial comparing sotalol and propranolol in chronic ventricular arrhythmia. ( Grace, M; Klinke, WP; Kubac, G, 1988) |
| "Many clinicians choose sotalol for the prevention of recurrences of atrial fibrillation (AF) as an alternative to quinidine, which has been associated with an increase in long-term mortality." | 8.80 | Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. ( Bauman, J; Southworth, MR; Viana, M; Zarembski, D, 1999) |
| "To study the incidence and mode of onset of early reinitiation of atrial fibrillation (ERAF) following successful internal cardioversion of chronic atrial fibrillation, and to determine the effects of sotalol in the prevention of ERAF." | 7.70 | Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. ( Ayers, GM; Lau, CP; Tse, HF, 1999) |
| "The effects of oral sotalol were compared with the findings obtained in the baseline study of a group of 26 consecutive patients with sustained monomorphic ventricular tachycardia or ventricular fibrillation and inducible ventricular tachycardia." | 7.67 | Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. ( Clement, DL; Jordaens, LJ; Palmer, A, 1989) |
| "Sotalol is a unique beta-blocking drug, possessing significant class III antiarrhythmic activity." | 6.67 | Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias. ( Anastasiou-Nana, MI; Anderson, JL; Freedman, RA; Gilbert, EM; Keefe, DL; MacNeil, DJ; Miller, RH; Saksena, S; Singh, S, 1991) |
| "Procainamide was successful in 13 (39%) patients." | 6.66 | Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study. ( Lidell, C; Rehnqvist, N; Rønnevik, PK; Sjögren, A; Yli-Uotila, RJ, 1985) |
| " We investigated the effects of pretreatment with oral d,l-sotalol on rate-dependent changes in atrial monophasic action potential (MAP) duration after cardioversion of chronic AF with reference to the efficacy in preventing the arrhythmia recurrence." | 5.11 | Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence. ( Ito, A; Kodama, I; Osaka, T; Yamazaki, M; Yokoyama, E, 2004) |
| "To compare the efficacy and safety of sotalol and quinidine after conversion of atrial fibrillation (AF) of <6 months, a prospective multicenter trial enrolled 121 patients who were randomized to receive dl-sotalol (160 to 320 mg/day, 58 patients) or quinidine sulfate (600 to 800 mg/day, 63 patients)." | 5.09 | Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo. ( de Paola, AA; Veloso, HH, 1999) |
| "To compare the effects of sotalol and metoprolol on heart rate, during isotonic (ITE) and isometric (IME) exercise and daily activities, in digitalized patients with chronic atrial fibrillation." | 5.09 | Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. ( Igoumenidis, NE; Kalebubas, MD; Kanoupakis, EM; Kochiadakis, GE; Mavrakis, HE; Vardakis, KE; Vardas, PE, 2001) |
| "Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven." | 5.08 | Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. ( Ferrick, KJ; Fisher, JD; Gallik, DM; Kim, SG; Roth, JA, 1997) |
| "To establish the value of adjuvant dl-sotalol to digoxin for control of the ventricular response in chronic atrial fibrillation, 60 patients were evaluated in a multicenter, randomized, double-blind, parallel, placebo-controlled study." | 5.07 | Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. ( Bellinger, R; Brodsky, M; Powers, L; Saini, R; Weiss, R; Zoble, R, 1994) |
| " Its relative efficacy towards suppressing chronic ventricular arrhythmia was tested by comparison with propranolol." | 5.06 | Randomized double blind trial comparing sotalol and propranolol in chronic ventricular arrhythmia. ( Grace, M; Klinke, WP; Kubac, G, 1988) |
| "In order to evaluate the negative inotropic effects of sotalol, metoprolol, and propranolol in patients with chronic stable angina pectoris, left ventricular ejection fraction (LVEF) was measured with radionuclide angiography and echocardiography." | 5.05 | Beta-blocker therapy evaluated by radionuclide angiography: a study in chronic stable angina. ( Lessem, J, 1982) |
| "Many clinicians choose sotalol for the prevention of recurrences of atrial fibrillation (AF) as an alternative to quinidine, which has been associated with an increase in long-term mortality." | 4.80 | Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. ( Bauman, J; Southworth, MR; Viana, M; Zarembski, D, 1999) |
| "To study the incidence and mode of onset of early reinitiation of atrial fibrillation (ERAF) following successful internal cardioversion of chronic atrial fibrillation, and to determine the effects of sotalol in the prevention of ERAF." | 3.70 | Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. ( Ayers, GM; Lau, CP; Tse, HF, 1999) |
| "The effects of oral sotalol were compared with the findings obtained in the baseline study of a group of 26 consecutive patients with sustained monomorphic ventricular tachycardia or ventricular fibrillation and inducible ventricular tachycardia." | 3.67 | Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. ( Clement, DL; Jordaens, LJ; Palmer, A, 1989) |
| "Sotalol is a unique beta-blocking drug, possessing significant class III antiarrhythmic activity." | 2.67 | Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias. ( Anastasiou-Nana, MI; Anderson, JL; Freedman, RA; Gilbert, EM; Keefe, DL; MacNeil, DJ; Miller, RH; Saksena, S; Singh, S, 1991) |
| "Procainamide was successful in 13 (39%) patients." | 2.66 | Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study. ( Lidell, C; Rehnqvist, N; Rønnevik, PK; Sjögren, A; Yli-Uotila, RJ, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (17.65) | 18.7374 |
| 1990's | 18 (52.94) | 18.2507 |
| 2000's | 9 (26.47) | 29.6817 |
| 2010's | 1 (2.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ermakov, S | 1 |
| Hoffmayer, KS | 1 |
| Gerstenfeld, EP | 1 |
| Scheinman, MM | 1 |
| Bestetti, R | 1 |
| Cardinalli-Neto, A | 1 |
| Scherer, M | 1 |
| Dzemali, O | 1 |
| Aybek, T | 1 |
| Wimmer-Greinecker, G | 1 |
| Moritz, A | 1 |
| Nattel, S | 2 |
| Osaka, T | 1 |
| Yamazaki, M | 1 |
| Yokoyama, E | 1 |
| Ito, A | 1 |
| Kodama, I | 1 |
| Thomsen, MB | 1 |
| Verduyn, SC | 2 |
| Stengl, M | 1 |
| Beekman, JD | 1 |
| de Pater, G | 1 |
| van Opstal, J | 1 |
| Volders, PG | 1 |
| Vos, MA | 2 |
| Narayan, G | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Lessem, J | 1 |
| Burckhardt, D | 1 |
| Pfisterer, M | 1 |
| Hoffmann, A | 1 |
| Burkart, F | 1 |
| Emmenegger, H | 1 |
| Jost, M | 1 |
| Bolli, P | 1 |
| Buehler, FR | 1 |
| Reimold, SC | 1 |
| Lamas, GA | 1 |
| Cantillon, CO | 1 |
| Antman, EM | 1 |
| Gorgels, AP | 1 |
| Lipcsei, GC | 1 |
| Wellens, HJ | 1 |
| Wang, J | 1 |
| Feng, J | 1 |
| Brodsky, M | 1 |
| Saini, R | 1 |
| Bellinger, R | 1 |
| Zoble, R | 1 |
| Weiss, R | 1 |
| Powers, L | 1 |
| Alt, E | 1 |
| Schmitt, C | 1 |
| Ammer, R | 1 |
| Plewan, A | 1 |
| Evans, F | 1 |
| Pasquantonio, J | 1 |
| Ideker, T | 1 |
| Lehmann, G | 1 |
| Pütter, K | 1 |
| Schömig, A | 1 |
| Lok, NS | 2 |
| Lau, CP | 4 |
| Gallik, DM | 1 |
| Kim, SG | 1 |
| Ferrick, KJ | 1 |
| Roth, JA | 1 |
| Fisher, JD | 1 |
| Hsieh, MH | 1 |
| Chen, SA | 1 |
| Wen, ZC | 1 |
| Tai, CT | 1 |
| Chiang, CE | 1 |
| Ding, YA | 1 |
| Chang, MS | 1 |
| Tse, HF | 2 |
| Ayers, GM | 2 |
| Wijffels, MC | 1 |
| Dorland, R | 1 |
| Allessie, MA | 1 |
| Fetsch, T | 2 |
| Burschel, G | 1 |
| Breithardt, G | 1 |
| Engberding, R | 1 |
| Koch, HP | 1 |
| Lukl, J | 1 |
| Trappe, HJ | 1 |
| Treese, N | 1 |
| Southworth, MR | 1 |
| Zarembski, D | 1 |
| Viana, M | 1 |
| Bauman, J | 1 |
| de Paola, AA | 1 |
| Veloso, HH | 1 |
| Kochiadakis, GE | 1 |
| Kanoupakis, EM | 1 |
| Kalebubas, MD | 1 |
| Igoumenidis, NE | 1 |
| Vardakis, KE | 1 |
| Mavrakis, HE | 1 |
| Vardas, PE | 1 |
| Kulmatycki, KM | 1 |
| Abouchehade, K | 1 |
| Sattari, S | 1 |
| Jamali, F | 1 |
| Areskog, NH | 1 |
| Cullhed, I | 1 |
| Ringqvist, I | 1 |
| Ström, G | 1 |
| Anastasiou-Nana, MI | 1 |
| Gilbert, EM | 1 |
| Miller, RH | 1 |
| Singh, S | 2 |
| Freedman, RA | 1 |
| Keefe, DL | 1 |
| Saksena, S | 1 |
| MacNeil, DJ | 1 |
| Anderson, JL | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| Van Gilst, WH | 1 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Lie, KI | 1 |
| Saini, RK | 1 |
| DiMarco, J | 1 |
| Kluger, J | 1 |
| Gold, R | 1 |
| Chen, YW | 1 |
| Jordaens, LJ | 1 |
| Palmer, A | 1 |
| Clement, DL | 1 |
| Kubac, G | 1 |
| Klinke, WP | 1 |
| Grace, M | 1 |
| Lidell, C | 1 |
| Rehnqvist, N | 1 |
| Sjögren, A | 1 |
| Yli-Uotila, RJ | 1 |
| Rønnevik, PK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00224341] | Phase 4 | 360 participants | Interventional | 2003-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sotalol and Chronic Disease
| Article | Year |
|---|---|
Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Humans; Quinidine; Secondary Preventio | 1999 |
16 trials available for sotalol and Chronic Disease
| Article | Year |
|---|---|
Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence.
Topics: Action Potentials; Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2004 |
Beta-blocker therapy evaluated by radionuclide angiography: a study in chronic stable angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Cardiac Volume; Chronic Disease; Echoc | 1982 |
Effects of the beta-adrenoceptor-blocking agent Sotalol on ventricular arrhythmias in patients with chronic ischemic heart disease. A placebo-controlled, double-blind cross-over study.
Topics: Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Blind Meth | 1983 |
Risk factors for the development of recurrent atrial fibrillation: role of pacing and clinical variables.
Topics: Atrial Fibrillation; Cardiac Pacing, Artificial; Chronic Disease; Female; Heart Atria; Heart Disease | 1995 |
Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group.
Topics: Atrial Fibrillation; Chronic Disease; Digoxin; Double-Blind Method; Drug Therapy, Combination; Elect | 1994 |
Effect of electrode position on outcome of low-energy intracardiac cardioversion of atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Catheterizat | 1997 |
Oxygen uptake kinetics and cardiopulmonary performance in lone atrial fibrillation and the effects of sotalol.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Exe | 1997 |
Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Female; Hemodynamics; Humans; Male; Midd | 1997 |
Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Chi-Square | 1998 |
[Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Dis | 1999 |
Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Female; Heart Rate; Human | 1999 |
Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Circadian | 2001 |
Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Chronic Disease; Circadian Rhythm; | 1991 |
Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group.
Topics: Atrial Fibrillation; Chronic Disease; Digoxin; Double-Blind Method; Electrocardiography, Ambulatory; | 1991 |
Randomized double blind trial comparing sotalol and propranolol in chronic ventricular arrhythmia.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Double-Bli | 1988 |
Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study.
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Dose-Response Relation | 1985 |
17 other studies available for sotalol and Chronic Disease
| Article | Year |
|---|---|
Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Chronic Disease; Dr | 2014 |
Implantable cardioverter defibrillator therapy for patients with chronic Chagas' disease: a randomized trial may not be necessary in high-risk patients.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Chagas Disease; Chronic Disease; | 2009 |
Impact of left atrial size reduction on chronic atrial fibrillation in mitral valve surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pac | 2003 |
Is atrial remodeling a viable target for prevention of atrial fibrillation recurrence?
Topics: Action Potentials; Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2004 |
Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Cardiac Complexes, Premature; Chronic Disea | 2004 |
Combined use of 1C and III agents for highly symptomatic, refractory atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Drug Combinations; Female | 2006 |
Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block.
Topics: Action Potentials; Animals; Cardiac Pacing, Artificial; Chronic Disease; Disease Models, Animal; Dog | 1995 |
Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
Topics: Aminobenzoates; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Bridged Bicyc | 1994 |
A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold.
Topics: Acute Disease; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Combined Modality Thera | 1997 |
Long-term outcome in patients with chronic atrial fibrillation after successful internal cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershoc | 1999 |
Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Disease Models, Animal; Elect | 1999 |
Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrilla | 1999 |
Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Antibodies, Monoclonal; Area Under Curve; Biolo | 2001 |
[Atrial fibrillation successfully converted. A new standard in the prevention of recurrence?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Calcium Ch | 2001 |
Cardiovascular and respiratory effects of the beta-adrenoceptive antagonist sotalol: studies in health, angina pectoris and obstructive lung disease.
Topics: Adult; Aged; Airway Resistance; Angina Pectoris; Blood Pressure; Chronic Disease; Exercise Test; Fem | 1975 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Chronic Disease; Drug Evaluation; Ele | 1989 |